Research Use Only. Not for use in diagnostic procedures.

PredictLung™
AI-Based Biomarker Research for Lung Cancer

Detecting oncogenic driver mutations and biomarkers in non-small cell lung cancer (NSCLC) from H&E-stained tissue images. 

The Growing Need for Rapid Biomarker Profiling

Lung cancer is one of the most prevalent malignancies and the leading cause of cancer-related mortality worldwide.

~27%

of people diagnosed with lung cancer
are alive 5 years later 1

Only ~36%

of patients with actionable biomarkers receive biomarker-matched therapy 2

Comprehensive genomic profiling can take several weeks, and some patients start treatment before results are available.

Non-small cell lung cancer (NSCLC) has multiple molecular subtypes, each with distinct treatment pathways.
The number of targeted therapies for NSCLC subtypes continues to grow, and this trend is expected to persist.

Biomarkers in the NCCN Guidelines® for NSCLC
EGFR
NTRK1/2/3 
ALK
KRAS
ERBB2 (HER2)
ROS1
BRAF
RET 
METex14 / cMET (protein)

Identifying actionable alterations helps guide first-line targeted therapy. Faster, tissue-sparing approaches to biomarker assessment are an active area of research.3,4

Barriers to Comprehensive Genomic Profiling today

Long turnaround

Often takes 3-5 weeks, in which case results are not available
for early  
treatment decisions.

Tissue-intensive

Consumes extra tumor tissue,
which is often scarce, especially in lung cancer. Leaves less material
for further diagnostic testing

Costly

Expensive, limiting access  

for many patients 
and
many 
healthcare systems 

PredictLung™: AI-Based Biomarker Research from H&E Images

PredictLung™ is being developed to analyze digitized H&E slides, which are already created for every lung biopsy, and generate biomarker-related probability outputs for research use.
How does it work? At the time of diagnosis, every patient undergoes a biopsy, which is then processed and stained with Hematoxylin and Eosin (H&E) so pathologists can evaluate the cancer, its aggressiveness, and isolate the tumor region for downstream genomic testing. PredictLung™ applies BioAI’s AI models to the digital H&E image to estimate the likelihood of specific genetic alterations. Because it uses an existing image, it does not consume additional tissue. PredictLung™ is under validation and is not intended for diagnosis, patient management or treatment selection.

Where PredictLung™ Fits

Pharma Biomarker Services

Custom H&E-based AI biomarker models and studies for pharma and research partners.

Clinical Trials

Exploring H&E- and IHC-based biomarker pre-screening to support clinical trial screening and enrollment.

Clinical Workflow

Upstream use in clinical laboratory workflows to refine and target definitive blood or tissue biomarker testing.

From H&E Slide to Biomarker Insights

Research Benefits

of existing digital slides

image taken from standard tissue slide after biopsy

across large retrospective cohorts

BioAI’s approach may be extended to other tumor types in research settings, such as breast, colorectal and prostate cancer.

PredictLung™ is intended for Research Use Only and is not intended for clinical diagnosis, patient management, treatment selection or use in diagnostic procedures. Any future clinical or regulated use would require further validation and applicable regulatory clearance, approval or laboratory validation.

References 

  1. State of Lung Cancer 2023 report. American Lung Association.  
https://www.lung.org/getmedia/186786b6-18c3-46a9-a7e7-810f3ce4deda/SOLC-2023-Print-Report.pdf 
  2. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022 Oct 6: https://pubmed.ncbi.nlm.nih.gov/36315914/  
  3. Oncogenic alterations in advanced NSCLC: a molecular super-highway
    https://doi.org/10.1186/s40364-024-00566-0  
  4. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer  
https://doi.org/10.1016/j.lanepe.2024.100839 
  5. NCCN Clinical Practice Guidelines in NSCLC Oncology 
https://jnccn.org/view/journals/jnccn/22/4/article-p249.xml 
  6. An Ensemble AI Model for RET Alteration Detection Using H&E Images as a Putative Screening Tool for More Efficient Genomic Alteration Detection 
https://doi.org/10.1089/aipo.2024.0015